会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Bicyclic enamide derivatives
    • 双环烯酰胺衍生物
    • US06603041B2
    • 2003-08-05
    • US09947107
    • 2001-09-05
    • Timothy John NormanJohn Robert PorterJohn Clifford HeadAndrew James Ratcliffe
    • Timothy John NormanJohn Robert PorterJohn Clifford HeadAndrew James Ratcliffe
    • C07C6112
    • C07D471/04A61K31/4375
    • Enamide derivatives of formula (1) are described: wherein R1 is a group Ar1L2Ar2Alk- in which Ar1 is an optionally substituted aromatic or heteroaromatic group, L2 is a covalent bond or a linker atom or group, Ar2 is an optionally substituted arylene or heteroarylene group and Alk is a chain —CH2—CH(R)—, —CH═C(R)— or  in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof; R2 is a hydrogen atom or a C1-6alkyl group; X is an O or S atom or the group NR30 group; j and k is each zero or the integer 1 or 2 provided that the sum of j and k is zero or the integer 1 or 2; Cy1 is an optionally substituted cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The componds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders, or disorders including the inappropriate growth or migration of cells.
    • 描述了式(1)的酰胺衍生物:其中R1是Ar1L2Ar2Alk-基团,其中Ar1是任选取代的芳族或杂芳族基团,L2是共价键或连接原子或基团,Ar 2是任选取代的亚芳基或杂亚芳基, Alk是链-CH 2 -CH(R) - , - CH = C(R) - 或其中R是羧酸(-CO 2 H)或其衍生物或生物试剂; R 2是氢原子或C 1-6烷基 基团; X是O或S原子或NR30基团; j和k各自为零或整数1或2,条件是j和k的和为零或整数1或2; Cy1是任选取代的脂环族 ,杂环脂族,芳族或杂芳族基团;及其盐,溶剂合物,水合物和N-氧化物。化合物能够抑制整联蛋白与其配体的结合,并且可用于预防和治疗免疫或炎症性疾病,或 疾病包括细胞不适当的生长或迁移。
    • 7. 发明授权
    • Cinnamic acid derivatives
    • 肉桂酸衍生物
    • US06329362B1
    • 2001-12-11
    • US09270408
    • 1999-03-16
    • Sarah Catherine ArchibaldJohn Clifford HeadGraham John WarrellowJohn Robert Porter
    • Sarah Catherine ArchibaldJohn Clifford HeadGraham John WarrellowJohn Robert Porter
    • A61K3103
    • C07D213/82A61K38/00C07C233/81C07K5/06139C07K5/06191Y10S514/826Y10S514/858Y10S514/863Y10S514/866Y10S514/885Y10S514/886Y10S514/887
    • Compounds of formula (1) are described: wherein L1 is a covalent bond or a linker atom or group; R is a carboxylic acid (—CO2H) or a derivative threof; R6 and R7 which may be the same or different is each an atom or group —L2(Alk2)tL3R12 in which L2, L3, Alk2 and t are as previously defined and R12 is a hydrogen or halogen atom or an —OR9, —NR9R10, —NO2, —CN, —CO2R9, —CONR9R10, —COR9, —N(R9)COR10, —N(R9)CSR10, —SO2N(R9)(R10), —N(R9)SO2R9, —N(R9)CON(R10)(R11), —N(R9)CSN(R10)(R11), —N(R9)SO2N(R10)(R11), or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group provided that R6 and R7 are not both hydrogen atoms and when R7 is a hydrogen atom then R4 and R5 is each a hydrogen or halogen atom or an alkyl, alkoxy or nitro group; and the salts, solvates, hydrates and N-oxides thereof, for use in modulating cell adhesion. The compounds are able to inhibit the binding of alpha 4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
    • 描述了式(1)的化合物:其中L 1是共价键或连接原子或基团; R是羧酸(-CO 2 H)或衍生物; R 6和R 7可以相同或不同,各自为原子或 基团-L2(Alk2)tL3R12,其中L2,L3,Alk2和t如前定义,R12是氢或卤素原子或-OR9,-NR9R10,-NO2,-CN,-CO2R9,-CONR9R10,-COR9 ,-N(R9)COR10,-N(R9)CSR10,-SO2N(R9)(R10),-N(R9)SO2R9,-N(R9)CON(R10)(R11) (R 10)(R 11),-N(R 9)SO 2 N(R 10)(R 11)或任选取代的脂族,杂脂族,脂环族,杂脂族,芳族或杂芳族基团,条件是R 6和R 7不是氢原子, 氢原子然后R4和R5各自为氢或卤素原子或烷基,烷氧基或硝基; 和其盐,溶剂合物,水合物和N-氧化物,用于调节细胞粘附。化合物能够抑制α4整联蛋白与其配体的结合,并且可用于预防和治疗免疫或炎症性疾病。
    • 9. 发明授权
    • 3-substituted isoquinolin-1-yl derivatives
    • 3-取代的异喹啉-1-基衍生物
    • US06469025B1
    • 2002-10-22
    • US09920206
    • 2001-08-01
    • John Clifford HeadCatherine McKayJohn Robert Porter
    • John Clifford HeadCatherine McKayJohn Robert Porter
    • C07D21722
    • C07D401/12C07D217/22C07D401/14C07D413/12
    • Squaric acid derivatives of formula (1) are described: wherein R1 is a hydrogen atom or a C1-6alkyl group; L1 is a covalent bond or a linker atom or group; Alk1 is an optionally substituted aliphatic chain; n is zero or the integer 1; R2 is a hydrogen atom or an optionally substitued heteroaliphatic, cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, heteropolycycloaliphatic, aromatic or heteroaromatic group; Alk is a chain —CH2CH(R)—, —CH═C(R)—,  in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof; Ar2 is an optionally substituted aromatic or heteroaromatic linking group; L2 is a covalent bond or a linker atom or group; R16 is the group —L3(Alk2)tL4R20 in which L3 and L4 which may be the same or different is each a covalent bond or a linker atom or group, t is zero or the integer 1, Alk2 is an optionally substituted aliphatic or heteroaliphatic chain and R20 is an optionally substituted aromatic or heteroaromatic group; The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders, or disorders including the inappropriate growth or migration of cells.
    • 描述式(1)的方酸衍生物:其中R1是氢原子或C1-6烷基; L1是共价键或连接原子或基团; Alk1是任选取代的脂族链; n是0或整数1 ; R2是氢原子或任选取代的杂脂族,脂环族,杂脂族,多环脂族,杂多环脂族,芳族或杂芳族基团; Alk是其中R是羧酸(-CO 2 H)或其衍生物或生物试剂的链; Ar 2是 任选取代的芳族或杂芳族连接基团; L2是共价键或连接原子或基团; R16是基团-L3(Alk2)tL4R20,其中L3和L4可以相同或不同,各自是共价键或连接基 原子或基团,t为零或整数1,Alk2为任选取代的脂族或杂脂族链,R20为任选取代的芳族或杂芳族基团;化合物能够抑制整联蛋白与其结合 并且可用于预防和治疗免疫或炎性疾病或包括细胞的不适当生长或迁移的病症。